Intratherapy or posttherapy FDG PET or FDG PET/CT for patients with head and neck cancer: A Systematic review and metaanalysis of prognostic studies

Sara Sheikhbahaei, Se Jin Ahn, Elizabeth Moriarty, Hyunseok Kang, Carole Fakhry, Rathan M. Subramaniam

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

OBJECTIVE. The objective of this study was to determine the predictive value of intratherapy or posttherapy FDG PET or FDG PET/CT with regard to overall survival (OS) and event-free survival (EFS) outcomes for patients with head and neck cancer (HNC). MATERIALS AND METHODS. A systematic search of the MEDLINE and EMBASE databases was performed. Studies in which PET/CT was performed during or after completion of primary therapy and for which survival outcomes were reported were included. OS and EFS were considered as outcomes. The pooled estimates of hazard ratios (HRs) and Mantel- Haenszel risk ratios (RRs) were generated for summary effects. RESULTS. Twenty-six studies were eligible for inclusion. The pooled HRs for OS (nine studies, 600 patients) and EFS (eight studies, 479 patients) were 3.55 (95% CI, 2.35-5.37) and 4.73 (95% CI, 2.61-8.56), respectively. Results from the RR analyses, including all 26 studies, showed that intratherapy or posttherapy PET/CT could significantly predict the 2-year and 3- to 5-year risk of death or disease progression. A positive PET result was associated with a more-than-sixfold increase in the risk of death within 2 years (2-year RR, 6.19 [95% CI, 3.04- 12.62]), which is attenuated-but remains significant-with longer follow-up (3- to 5-year RR, 2.42 [95% CI, 1.76-3.32]). The estimated pooled RRs for 2-year mortality were 8.31 (95% CI, 3.83-18.01) for posttherapy PET/CT versus 3.99 (95% CI, 1.43-11.10) for intratherapy PET/CT. CONCLUSION. Positive results of intratherapy or posttherapy PET/CT examinations strongly predict the risk of adverse events and death, particularly within 2 years but also up to 5 years, for patients with HNC.

Original languageEnglish (US)
Pages (from-to)1103-1113
Number of pages11
JournalAmerican Journal of Roentgenology
Volume205
Issue number5
DOIs
StatePublished - Jan 1 2015

Fingerprint

Head and Neck Neoplasms
Odds Ratio
Disease-Free Survival
Survival
MEDLINE
Disease Progression
Databases
Mortality
Therapeutics

Keywords

  • Fdg pet/ct
  • Head and neck cancer
  • Meta-analysis
  • Prognosis
  • Therapy assessment

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Intratherapy or posttherapy FDG PET or FDG PET/CT for patients with head and neck cancer : A Systematic review and metaanalysis of prognostic studies. / Sheikhbahaei, Sara; Ahn, Se Jin; Moriarty, Elizabeth; Kang, Hyunseok; Fakhry, Carole; Subramaniam, Rathan M.

In: American Journal of Roentgenology, Vol. 205, No. 5, 01.01.2015, p. 1103-1113.

Research output: Contribution to journalReview article

@article{4b1406efe5bc4a9888a3bde0ca158aba,
title = "Intratherapy or posttherapy FDG PET or FDG PET/CT for patients with head and neck cancer: A Systematic review and metaanalysis of prognostic studies",
abstract = "OBJECTIVE. The objective of this study was to determine the predictive value of intratherapy or posttherapy FDG PET or FDG PET/CT with regard to overall survival (OS) and event-free survival (EFS) outcomes for patients with head and neck cancer (HNC). MATERIALS AND METHODS. A systematic search of the MEDLINE and EMBASE databases was performed. Studies in which PET/CT was performed during or after completion of primary therapy and for which survival outcomes were reported were included. OS and EFS were considered as outcomes. The pooled estimates of hazard ratios (HRs) and Mantel- Haenszel risk ratios (RRs) were generated for summary effects. RESULTS. Twenty-six studies were eligible for inclusion. The pooled HRs for OS (nine studies, 600 patients) and EFS (eight studies, 479 patients) were 3.55 (95{\%} CI, 2.35-5.37) and 4.73 (95{\%} CI, 2.61-8.56), respectively. Results from the RR analyses, including all 26 studies, showed that intratherapy or posttherapy PET/CT could significantly predict the 2-year and 3- to 5-year risk of death or disease progression. A positive PET result was associated with a more-than-sixfold increase in the risk of death within 2 years (2-year RR, 6.19 [95{\%} CI, 3.04- 12.62]), which is attenuated-but remains significant-with longer follow-up (3- to 5-year RR, 2.42 [95{\%} CI, 1.76-3.32]). The estimated pooled RRs for 2-year mortality were 8.31 (95{\%} CI, 3.83-18.01) for posttherapy PET/CT versus 3.99 (95{\%} CI, 1.43-11.10) for intratherapy PET/CT. CONCLUSION. Positive results of intratherapy or posttherapy PET/CT examinations strongly predict the risk of adverse events and death, particularly within 2 years but also up to 5 years, for patients with HNC.",
keywords = "Fdg pet/ct, Head and neck cancer, Meta-analysis, Prognosis, Therapy assessment",
author = "Sara Sheikhbahaei and Ahn, {Se Jin} and Elizabeth Moriarty and Hyunseok Kang and Carole Fakhry and Subramaniam, {Rathan M.}",
year = "2015",
month = "1",
day = "1",
doi = "10.2214/AJR.15.14647",
language = "English (US)",
volume = "205",
pages = "1103--1113",
journal = "American Journal of Roentgenology",
issn = "0361-803X",
publisher = "American Roentgen Ray Society",
number = "5",

}

TY - JOUR

T1 - Intratherapy or posttherapy FDG PET or FDG PET/CT for patients with head and neck cancer

T2 - A Systematic review and metaanalysis of prognostic studies

AU - Sheikhbahaei, Sara

AU - Ahn, Se Jin

AU - Moriarty, Elizabeth

AU - Kang, Hyunseok

AU - Fakhry, Carole

AU - Subramaniam, Rathan M.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - OBJECTIVE. The objective of this study was to determine the predictive value of intratherapy or posttherapy FDG PET or FDG PET/CT with regard to overall survival (OS) and event-free survival (EFS) outcomes for patients with head and neck cancer (HNC). MATERIALS AND METHODS. A systematic search of the MEDLINE and EMBASE databases was performed. Studies in which PET/CT was performed during or after completion of primary therapy and for which survival outcomes were reported were included. OS and EFS were considered as outcomes. The pooled estimates of hazard ratios (HRs) and Mantel- Haenszel risk ratios (RRs) were generated for summary effects. RESULTS. Twenty-six studies were eligible for inclusion. The pooled HRs for OS (nine studies, 600 patients) and EFS (eight studies, 479 patients) were 3.55 (95% CI, 2.35-5.37) and 4.73 (95% CI, 2.61-8.56), respectively. Results from the RR analyses, including all 26 studies, showed that intratherapy or posttherapy PET/CT could significantly predict the 2-year and 3- to 5-year risk of death or disease progression. A positive PET result was associated with a more-than-sixfold increase in the risk of death within 2 years (2-year RR, 6.19 [95% CI, 3.04- 12.62]), which is attenuated-but remains significant-with longer follow-up (3- to 5-year RR, 2.42 [95% CI, 1.76-3.32]). The estimated pooled RRs for 2-year mortality were 8.31 (95% CI, 3.83-18.01) for posttherapy PET/CT versus 3.99 (95% CI, 1.43-11.10) for intratherapy PET/CT. CONCLUSION. Positive results of intratherapy or posttherapy PET/CT examinations strongly predict the risk of adverse events and death, particularly within 2 years but also up to 5 years, for patients with HNC.

AB - OBJECTIVE. The objective of this study was to determine the predictive value of intratherapy or posttherapy FDG PET or FDG PET/CT with regard to overall survival (OS) and event-free survival (EFS) outcomes for patients with head and neck cancer (HNC). MATERIALS AND METHODS. A systematic search of the MEDLINE and EMBASE databases was performed. Studies in which PET/CT was performed during or after completion of primary therapy and for which survival outcomes were reported were included. OS and EFS were considered as outcomes. The pooled estimates of hazard ratios (HRs) and Mantel- Haenszel risk ratios (RRs) were generated for summary effects. RESULTS. Twenty-six studies were eligible for inclusion. The pooled HRs for OS (nine studies, 600 patients) and EFS (eight studies, 479 patients) were 3.55 (95% CI, 2.35-5.37) and 4.73 (95% CI, 2.61-8.56), respectively. Results from the RR analyses, including all 26 studies, showed that intratherapy or posttherapy PET/CT could significantly predict the 2-year and 3- to 5-year risk of death or disease progression. A positive PET result was associated with a more-than-sixfold increase in the risk of death within 2 years (2-year RR, 6.19 [95% CI, 3.04- 12.62]), which is attenuated-but remains significant-with longer follow-up (3- to 5-year RR, 2.42 [95% CI, 1.76-3.32]). The estimated pooled RRs for 2-year mortality were 8.31 (95% CI, 3.83-18.01) for posttherapy PET/CT versus 3.99 (95% CI, 1.43-11.10) for intratherapy PET/CT. CONCLUSION. Positive results of intratherapy or posttherapy PET/CT examinations strongly predict the risk of adverse events and death, particularly within 2 years but also up to 5 years, for patients with HNC.

KW - Fdg pet/ct

KW - Head and neck cancer

KW - Meta-analysis

KW - Prognosis

KW - Therapy assessment

UR - http://www.scopus.com/inward/record.url?scp=84944909729&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944909729&partnerID=8YFLogxK

U2 - 10.2214/AJR.15.14647

DO - 10.2214/AJR.15.14647

M3 - Review article

C2 - 26496559

AN - SCOPUS:84944909729

VL - 205

SP - 1103

EP - 1113

JO - American Journal of Roentgenology

JF - American Journal of Roentgenology

SN - 0361-803X

IS - 5

ER -